Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CyclopharmASX:CYC 27 EV-to-OCF is -3.95 as of Aug. 12, 2026. GuruFocus rates ASX:CYC with a GF Score™ of 27/100 and a GF Value™ of A$0.82 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 853 Medical Devices & Instruments companies, Cyclopharm ranks better than 70.69% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Cyclopharm's Enterprise Value is A$68.38 Mil.
Cyclopharm's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was A$-17.33 Mil. Therefore, Cyclopharm's EV-to-OCF for today is -3.95.
The historical rank and industry rank for Cyclopharm's EV-to-OCF or its related term are showing as below:
ASX:CYC'
s EV-to-OCF Range Over the Past 10 Years
Min: -351.95 Med: -18.41 Max: 525.83
Current: -4.02
During the past 13 years, the highest EV-to-OCF of Cyclopharm was 525.83. The lowest was -351.95. And the median was -18.41.
ASX:CYC's EV-to-OCF is ranked better than 70.69% of 853
companies
in the Medical Devices & Instruments industry
Industry Median: 7.94
vs ASX:CYC: -4.02
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Cyclopharm's share price for today is A$0.535.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Cyclopharm's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.157.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Cyclopharm EV-to-OCF Related Terms
Cyclopharm EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Cyclopharm's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Cyclopharm's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cyclopharm EV-to-OCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Cyclopharm's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Cyclopharm's EV-to-OCF falls into.
Cyclopharm's current Enterprise Value is A$68.38 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Cyclopharm's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was A$-17.33 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cyclopharm (ASX:CYC) has a EV-to-OCF of -3.95 as of Aug. 12, 2026. According to the industry distribution chart, Cyclopharm ranks #250 out of 853 companies in the Medical Devices & Instruments industry, placing it in the top 29.3%.
Is Cyclopharm's EV-to-OCF too high?
Cyclopharm's current EV-to-OCF is -3.95. Based on the distribution chart, Cyclopharm ranks #250 out of 853 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Cyclopharm has a GF Score™ of 27/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cyclopharm's EV-to-OCF compare to MCK and COR?
According to the Medical Devices & Instruments industry distribution chart, Cyclopharm ranks #250 out of 853 companies for EV-to-OCF. This puts Cyclopharm in the upper half of its industry. The industry median EV-to-OCF is 7.94. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Medical Devices & Instruments company?
The median EV-to-OCF among Medical Devices & Instruments companies is 7.94, based on 853 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median EV-to-OCF is 7.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cyclopharm's current EV-to-OCF is -3.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cyclopharm stock overvalued right now?
Based on GuruFocus' analysis, Cyclopharm (ASX:CYC) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.82, compared to a current price of A$0.54 — trading 34.8% below its estimated fair value. The current EV-to-OCF is -3.95. Cyclopharm's overall GF Score™ is 27/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Cyclopharm (ASX:CYC), the current EV-to-OCF is -3.95 as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cyclopharm (ASX:CYC) Overvalued in 2026?
Based on GuruFocus' analysis, Cyclopharm stock appears to be undervalued.
The current stock price of A$0.54 is trading 34.8% below its estimated GF Value™ of A$0.82.
GuruFocus considers Cyclopharm to be Possible Value Trap.
Key valuation signals for ASX:CYC:
EV-to-OCF: -3.95
GF Value™: A$0.82 vs. price of A$0.54 (34.8% below fair value)
No single metric tells the full story. See the ASX:CYC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cyclopharm Ltd is a health technology company offering solutions related to functional lung ventilation imaging. Its proprietary product Technegas is a broad-spectrum diagnostic lung imaging technology product for the visualisation of pulmonary ventilation and lung function. The company sells its products to healthcare institutions and medical professionals. Maximum revenue is generated from its Technegas products and services, which include the sale of diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism and other respiratory conditions. Geographically, the company generates maximum revenue from its business in Europe, and the rest from Asia Pacific, Canada, the USA, and other regions.
27GF Score
Get the complete analysis for ASX:CYC
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CYC has been successfully added to your 
